Many studies using P2X7 inhibitors and antagonist have rendered promising results, reducing cancer growth or spreading in preclinical animal models of colon cancer (Adinolfi et al., 2012), breast cancer (Jelassi et al., 2011; Park et al., 2016), ovarian cancer (Vázquez-Cuevas et al., 2014), pancreatic ductal adenocarcinoma (Giannuzzo et al., 2016), neuroblastoma (Amoroso et al., 2015), melanoma (Adinolfi et al., 2012, 2015), glioma (Ryu et al., 2011), and mesothelioma (Amoroso et al., 2016). Here, P2RX7 is linked to central nervous system cancer.